Correlation of Nuclear Factor Erythroid 2-Related Factor (NRF2) Expression Level with the Efficacy of Brusatol in Urothelial Cell Carcinoma Cell Lines

Background and Aim: Bladder cancer (BC) IS the second most common genitourinary tumour and the fourth most common cancer in men. BC is highly responsive to use the cisplatin based chemotherapy initially, resistance to the platinum based chemotherapy drug develops rapidly which is a major challenge in management of BC facing clinicians. High expression of Nuclear Factor Erythroid 2-related factor (NRF-2) was noticed in different types of cancers. Recently, genetic analyses of human tumours have indicated that NRF2 Overexpression may be cause resistance to chemotherapy. The aim of this study is to determine whether basal Nrf-2 expression correlates with the ability of Brusatol to attenuate Cisplatin resistance. Methodology: Four urothelial cell cancer (UCC) cell line cultured, Cisplatin dosing, BCA Assay and Western immunoblot done for all 4 UCC cell lines in order to determine the efficacy of brusatol on Cisplatin cytotoxicity action and to established the basal Nrf-2 expression in different UCC cell lines. Results: The results which were obtained prove the hypothesis we were working on. Conclusion: there is a significant synergistic relationship between Brusatol and Cisplatin co-administration.